Johnson, J. S., Miller, J. W., Hatoum, F., Schell, M. J., Yu, X., Souza, G. R., Mizelle, S., Gullapalli, K., Fazili, A., Jain, R., Chatzkel, J., Cen, L., Dhillon, J., Cubitt, C., Yao, J., Whiting, J., Li, J., Swank, J., Jameel, G., Zhang, J., Wang, X., Spiess, P. E., Fishman, M., Chahoud, J. (2026). Pembrolizumab plus high-dose IL-2 in advanced clear cell renal cell carcinoma: six-year survival outcomes and molecular signatures from a phase 2 trial. Nature Communications. https://doi.org/10.1038/s41467-026-73336-1